Cal­lid­i­tas wins full ap­proval for steroid drug in rare au­toim­mune dis­ease

Cal­lid­i­tas Ther­a­peu­tics con­vert­ed its ac­cel­er­at­ed ap­proval for Tarpeyo in pri­ma­ry im­munoglob­u­lin A nephropa­thy (IgAN) to a full ap­proval, mark­ing what it says is an im­por­tant …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER